The common goal is the advancement of women’s health and welfare, through tackling the most burdensome crisis facing the female population, such as cervical cancer.
NTL Healthcare, Participates in the 2021 AI EXPO Korea
NTL Healthcare introduced new Artificial Intelligence (AI) technology at the ‘2021 AI EXPO KOREA’.
NTL Healthcare (CEO, Tae-hee Kim) participated in ‘2021 AI EXPO KOREA’ held at COEX in Samseong-dong, Seoul for 3 days from 24th to 26th and unveiled “CerviCARE AI,” a cervical cancer screening system.
The CerviCARE AI is a system that utilizes 6 million cervical imaging big data that NTL has accumulated over the past 25 years, and it classifies the normal into normal and abnormal, as well as negative and positive evaluation of cervix. Abnormal created a learning model that was subdivided into low-grade lesion, high-grade lesion, and cancer, and conducted more than 300,000 data verification. In addition, NTL applied for medical device license (grade 3) approval from the Ministry of Food and Drug Safety based on the results of clinical trials in Korea for domestic and foreign screening services of CerviCARE AI.
NTL introduced “CerviCARE AI” at the AI EXPO KOREA and had a time to communicate with visitors by questioning and answering questions.
NTL Healthcare provides various screening services such as screening for women’s cancer not only cervical cancer, and has plans to continue to develop and supply new products that can improve women’s diseases.